Periconceptual prednisolone therapy for the management of recurrent pregnancy loss

Abstract

Background: Recurrent miscarriage has been investigated for a long time with different types of therapeutic trials for those with unknown cause. Prednisolone as an immune modulator agent can have beneficial effect in improving pregnancy outcome in those patients. Objective: The aim of this study was to investigate the role prednisolone in preventing miscarriage in patients with recurrent pregnancy loss. Methods: Sixty two patients enrolled in this study, all of them have recurrent miscarriage, after investigations and exclusion of those with antiphspholipid syndrome, medical disease, endocrine disorder and uterine pathology. Patients divided randomly and equally into two groups. Study group give prednisolone therapy 5 mg orally for two months prior to conception & continue during pregnancy till 13 weeks of gestation, while the second group received folic acid 5mg orally before conception and continue till the end of first trimester. Patients were followed up throughout pregnancy till delivery.Results: There was significant association between pregnancy outcome and type of treatment majority (90.3%, n=28) of patients using prednisolone continue treatment, while only (38.7%, n=12) of control group continue their pregnancy. (X 2 =18.03, P=<0.001). Conclusion: Periconseptual prednisolone therapy can have dramatic improvement in the outcome of pregnancy in those who suffer from recurrent miscarriage

Potential effect of lemongrass oil extract (Cymbopogon citratus) against Streptococcus mitis (primary periodontal colonizers)

“…The relative quantification method (2-Ct method) was used to calculate the expression levels of the S. mitis genes from cDNA using qRT-PCR. The fold-change in gene expression was normalized to the GAPDH gene as a housekeeping gene and compared to a calibrator sample [30] . Quantitative nucleic acid amplification tests (QNAT) is the preferred method for S. mitis surveillance to guide the application of preemptive antibacterial therapy [31].…”